Related references
Note: Only part of the references are listed.Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement
Virginia A. Moyer
ANNALS OF INTERNAL MEDICINE (2012)
Prostate-Specific Antigen and Long-Term Prediction of Prostate Cancer Incidence and Mortality in the General Population
David D. Orsted et al.
EUROPEAN UROLOGY (2012)
Individualized Estimation of the Benefit of Radical Prostatectomy from the Scandinavian Prostate Cancer Group Randomized Trial
Andrew Vickers et al.
EUROPEAN UROLOGY (2012)
Temporal Trends in Cause of Death Among Swedish and US Men with Prostate Cancer
Mara M. Epstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Prostate-Cancer Mortality at 11 Years of Follow-up
Fritz H. Schroder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Quality-of-Life Effects of Prostate-Specific Antigen Screening
Eveline A. M. Heijnsdijk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Radical Prostatectomy versus Observation for Localized Prostate Cancer
Timothy J. Wilt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
Anna Bill-Axelson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Risk Profiles and Treatment Patterns Among Men Diagnosed as Having Prostate Cancer and a Prostate-Specific Antigen Level Below 4.0 ng/mL
Yu-Hsuan Shao et al.
ARCHIVES OF INTERNAL MEDICINE (2010)
Balancing the Harms and Benefits of Early Detection of Prostate Cancer
Pim J. van Leeuwen et al.
CANCER (2010)
Baseline PSA as a Predictor of Prostate Cancer-Specific Mortality Over the Past 2 Decades Duke University Experience
Ping Tang et al.
CANCER (2010)
Empirical Estimates of the Lead Time Distribution for Prostate Cancer Based on Two Independent Representative Cohorts of Men Not Subject to Prostate-Specific Antigen Screening
Caroline J. Savage et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)
The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group
Andrew J. Vickers et al.
CLINICAL CANCER RESEARCH (2010)
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study
Andrew J. Vickers et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context
Gerrit Draisma et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening: 1986-2005
H. Gilbert Welch et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Clinical Risk Factors, DNA Variants, and the Development of Type 2 Diabetes.
Valeriya Lyssenko et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends
Donatello Telesca et al.
BIOMETRICS (2008)
The surgical learning curve for prostate cancer control after radical prostatectomy
Andrew J. Vickers et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years
Hans Lilja et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability
H. Ballentine Carter et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Assessing prostate cancer risk: Results from the prostate cancer prevention trial
IM Thompson et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at-20°C
D Ulmert et al.
CLINICAL CHEMISTRY (2006)
Lead time associated with screening for prostate cancer
M Tornblom et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Share Paper
